An evaluation comparing Californium252 neutron brachytherapy with neoadjuvant intra-arterial embolism chemotherapy assisted surgery effect for treating advanced cervical carcinoma patients

Purpose of investigation: To compare the therapeutic and side effects of using Californium252 (252Cf) neutron brachytherapy with neoadjuvant intra-arterial embolism chemotherapy in combination with surgery for treating Stage Ib2-IIb cervical cancers (CCs). Materials and Methods: Thirty-two Stage Ib2-IIb CC patients were enrolled and randomly divided into two groups from January 2007 to April 2010 in the present Hospital. Prior to surgery within four weeks, a total of 17 cases were treated with 252Cf neutron brachytherapy (700-800 cGy doses at point A) once a week (Group A), and 15 cases were treated by neoadjuvant intra-arterial embolism chemotherapy using a combination of bleomycin, carboplatin, and cyclophosphamide twice (Group B). The clinical symptoms and signs, side effects, and relapse condition follow up until July 2013 were compared between the two groups for the perioperation. Results: Reductions in tumor mass and CR+PR were not significantly different between the groups before the surgery (p > 0.05). Abdominal pain and pelvic adhesions were significantly more severe in Group B (p < 0.05). There were no significant differences in surgical time, blood loss or the other side effects between Groups A and B (p > 0.05). The percentage of pelvic tumor recurrences in Group A was lower than that of the patients in Group B (11.8% vs 20.0%) although with no significant difference at present. No distant metastasis has been found in both two groups. Conclusion: Except for less abdominal pain and pelvic adhesions, 252Cf neutron brachytherapy has perioperative effects similar to those of neoadjuvant intra-arterial embolism chemotherapy.

Advanced cervical cancer; Neoadjuvant intra-arterial embolism chemotherapy; Californium252 neutron brachytherapy.

[1] Zhang W., Huang M., Li S., Wu L., Li N., Zhang X., et al.” A comparative study of digital colposcope and optical colposcope in the diagnosis of early lesions of uterine cervix”. Zhonghua Zhong Liu Za Zhi, 2002, 24, 570.

[2] Shen Y., Wang P., Li Y.,Ye F., Wang F., Wan X., et al.: “miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer”. Br. J. Cancer, 2013, 109, 92.

[3] Schlea C.S., Stoddard D.H.: “Californium isotopes proposed for intracavitary and interstitial radiation therapy with neutrons”. Nature, 1965, 206, 1058.

[4] Zhang M., Xu H.D., Pan S.D., Lin S., Yue J.H., Liu J.R.: “Low-doserate californium-252 neutron intracavitary after loading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer”. Int. J. Radiat. Oncol. Biol. Phys., 2012, 83, 966.

[5] Lei X., Qian C.Y., Qing Y., Zhao K.W., Yang Z.Z., Dai N., et al.: “Californium-252 brachytherapy combined with external-beam radiotherapy for cervical cancer: long-term treatment results”. Int. J. Radiat. Oncol. Biol. Phys., 2011, 81, 1264.

[6] Shoji T., Takatori E., Saito T., Omi H., Kagabu M., Miura F., et al.: “Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix”. Cancer Chemother. Pharmacol., 2013, 71, 657.

[7] Yee G.P., De Souza P., Khachigian L.M.: “Current and potential treatments for cervical cancer”. Curr. Cancer Drug Targets, 2013, 13, 205.

[8] Okines A.F., Morris R., Hancock B.W.: “An evaluation of FIGO 2000: the first 5 years”. J. Reprod. Med., 2008, 53, 615.

[9] Thompson S., Delaney G., Gabriel G.S., Jacob S., Das P., Barton M.: “Estimation of the optimal brachytherapy utilization rate in the treatment of carcinoma of the uterine cervix: review of clinical practice guidelines and primary evidence”. Cancer, 2006, 107, 2932.

[10] Wen H., Wu X., Li Z.,Wang H., Zang R., Sun M., et al.: “A prospective randomized controlled study on multiple neoadjuvant treatments for patients with stage IB2 to IIA cervical cancer”. Int. J. Gynecol. Cancer, 2012, 22, 296.

[11] Kaneyasu Y., Nagai N., Nagata Y., Hashimoto Y., Yuki S., Murakami Y., et al.: “Intra-arterial infusion chemotherapy using cisplatin with radiotherapy for Stage III squamous cell carcinoma of the cervix”. Int. J. Radiat. Oncol. Biol. Phys., 2009, 75, 369.

[12] Park S.Y., Kim B.G., Kim J.H., Lee J.H., Lee E.D., Lee K.H., et al.: “Phase I/II study of neoadjuvant intraarterial chemotherapy with mitomycin- C, vincristine, and cisplatin in patients with stage IIb bulky cervical carcinoma”. Cancer, 1995, 76, 814.

[13] Tacev T., Ptackova B., Stmad V.: “Califomium-252(252Cf) versus conventional gamma radiation in the brachytherapy of advanced cervical carcinoma long-term treatment results of a randomized study”. Strahlenther. Onkol., 2003, 179, 377.

[14] Maruyama Y., Yoneda J., Krolikiewicz H., Mendiondo O., Beach J.L., Coffey C.W. 2nd, et al.: “A clinical trial for advanced cervicovaginal pelvis carcinomas using californium-252 fast neutron therapy: report of early responses”. Int J Radiat Oncol Biol Phys. 1980;6(12):1629–1637.

[15] Rivard M.J., Kirk B.L., Stapleford L.J.,Wazer D.E.: “A comparison of the expected costs of high dose rate brachytherapy using 252Cf versus 192Ir”. Appl. RadiatIsot., 2004, 61, 1211.

[16] Vallejo A., Hilaris B.S., Anderson L.L.: “Californium-252 interstitial implantation: a clinical study at Memorial Hospital”. Int. J. Radiat. Oncol. Biol. Phys., 1977, 2, 731.

[17] vanPutten L.M.: “Reoxygenation of hypoxic tumor cells”. Strahlentherapie, 1977, 153, 380.

[18] Radice E., Dozois R.R.: “Locally recurrent rectal cancer”. Dig. Surg., 2001, 18, 355.

[19] Song H.,Yanch J.C.: “Acceletator-based neutron brachytherapy”. Med. Phys., 2002, 29, 15.